VeraDermics Inc (MANE)
NYSEHealth CareBiotechnologySnapshot 2026-09-04
$98.51+0.78%
Close 2026-09-04 · 1-day change
NYSEHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MANE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -42.0% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
MANE — earnings in line
Dated 2026-08-11
of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Why it matters: Earnings results will show if the company meets expectations and controls losses.
Watch forQ2 earnings show a profit or smaller loss than the previous quarter's negative $29.9 million.
Also watch forQ2 earnings report shows a larger loss than negative $29.9 million.
Why it matters: More capital raises will show how well the company is managing funding needs.
Supportive ifThere is news of a capital raise over $100 million.
Worry ifNo new capital raise announced by the end of 2026.
Why it matters: Cash position updates will show financial health and ability to fund trials. Good cash helps VDPHL01.
Supportive ifCash stays over $390 million after capital raises. This helps operations until 2030.
Worry ifCash drops below $390 million. This raises concerns about future funding.
Why it matters: Trends in operating losses will show if the company manages cash flow well.
Worry ifOperating losses were less than negative $29.9 million in Q2.
Less concerning ifOperating losses were more than negative $29.9 million in Q2.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$271 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $730 loss on $10,000 · 7.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,484 loss on $10,000 · 24.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Updates on cash reserves will show if the company can keep running until 2029.
Supportive ifCash balance reported above $390 million after Q1 2026.
Worry ifCash balance reported below $390 million after Q1 2026.
Why it matters: More spending on R&D may mean faster clinical development but could increase losses.
Worry ifR&D costs were over $25 million for Q2 2026, showing strong investment in trials.
Less concerning ifR&D costs were under $25 million. This shows slower progress in clinical development.
Why it matters: Having less cash than this may worry investors about funding future work.
Worry ifCash over $350 million shows strong financial health for operations.
Less concerning ifCash falls below $350 million, raising worries about funding and staying in business.
Why it matters: Topline results will show if VDPHL01 is effective for male pattern hair loss. This is key for the product's future.
Supportive ifStudy 304 shows that hair growth improved a lot compared to placebo.
Worry ifStudy 304 shows no big difference in hair growth compared to placebo.
Why it matters: This data will provide insights into the long-term effectiveness of VDPHL01 for men.
Supportive ifStudy 302 shows that male participants had steady hair growth and safety over 12 months.
Worry if12-month data from Study 302 shows no sustained improvement in hair growth.
Why it matters: Topline results will indicate if VDPHL01 can become the first oral treatment for women with pattern hair loss.
Supportive ifStudy 306 shows that women had a big improvement in hair growth.
Worry ifStudy 306 shows no big improvement in hair growth for women.